Back to Authors

Yazdany, Jinoos

https://orcid.org/0000-0002-3508-4094

Mayo Clinic

University of California, San Francisco

Citations 12

Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures
Myslinski, Rachel, Miller, Amy S., Francisco, Melissa, Desai, Sonali , Schmajuk, Gabriela , Barber, Claire , Orozco, Catalina, Bunyard, Matthew, Bergman, Martin , Passo, Murray H., Matteson, Eric L. , Olson, Richard D. , Silverman, Stuart L. , Warren, Robert W. , Nola, Kamala , Yazdany, Jinoos , Lacaille, Diane V. , Robbins, Mark L. , Barber, Claire E H

Arthritis Care & Research | July 7, 2016 | Volume: 68 | Issue: 10 | Pages: 1402-1409

10.1002/acr.22985 Get It

Mapping Perceptions of Lupus Medication Decision‐Making Facilitators: The Importance of Patient Context
Qu, Haiyan , Shewchuk, Richard M. , Leong, Amye , Dall’Era, Maria , Singh, Jasvinder A. , Alarcón, Graciela S. , Fraenkel, Liana , Yazdany, Jinoos , Singh, Jasvinder A

Arthritis Care & Research | April 10, 2016 | Volume: 68 | Issue: 12 | Pages: 1787-1794

10.1002/acr.22904 Get It

ObjectiveNumerous factors can impede or facilitate patients’ medication decision‐making and adherence to physicians’ recommendations. Little is known about how patients and physicians jointly view issues that affect the decision‐making process. Our objective was to derive an empirical framework of patient‐identified facilitators to lupus medication decision‐making from key stakeholders (including 15 physicians, 5 patients/patient advocates, and 8 medical professionals) using a patient‐centered cognitive mapping approach.MethodsWe used nominal group patient panels to identify facilitators to lupus treatment decision‐making. Stakeholders independently sorted the identified facilitators (n = 98) based on their similarities and rated the importance of each facilitator in patient decision‐making. Data were analyzed using multidimensional scaling and hierarchical cluster analysis.ResultsA cognitive map was derived that represents an empirical framework of facilitators for lupus treatment decisions from multiple stakeholders’ perspectives. The facilitator clusters were 1) hope for a normal/healthy life, 2) understand benefits and effectiveness of taking medications, 3) desire to minimize side effects, 4) medication‐related data, 5) medication effectiveness for “me,” 6) family focus, 7) confidence in physician, 8) medication research, 9) reassurance about medication, and 10) medication economics.ConclusionConsideration of how different stakeholders perceive the relative importance of lupus medication decision‐making clusters is an important step toward improving patient‐physician communication and effective shared decision‐making. The empirically derived framework of medication decision‐making facilitators can be used as a guide to develop a lupus decision aid that focuses on improving physician‐patient communication.